Teva Pharmaceutical Industries (TEVA) Expected to Announce Quarterly Sales of $4.80 Billion

Equities research analysts forecast that Teva Pharmaceutical Industries (NYSE:TEVA) will report $4.80 billion in sales for the current quarter, according to Zacks. Seven analysts have issued estimates for Teva Pharmaceutical Industries’ earnings, with the lowest sales estimate coming in at $4.68 billion and the highest estimate coming in at $4.96 billion. Teva Pharmaceutical Industries posted sales of $5.63 billion in the same quarter last year, which would indicate a negative year over year growth rate of 14.7%. The company is expected to announce its next quarterly earnings results before the market opens on Thursday, May 3rd.

According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full-year sales of $18.65 billion for the current fiscal year, with estimates ranging from $18.49 billion to $18.80 billion. For the next fiscal year, analysts anticipate that the business will post sales of $18.01 billion per share, with estimates ranging from $17.65 billion to $18.65 billion. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.14. The company had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.29 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The firm’s revenue for the quarter was down 15.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.38 EPS.

A number of research analysts have weighed in on TEVA shares. Goldman Sachs raised their price objective on Teva Pharmaceutical Industries from $20.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, January 11th. Susquehanna Bancshares reiterated a “positive” rating and set a $24.00 price target (up previously from $22.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, January 25th. ValuEngine upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 11th. Citigroup upgraded Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 price target on the stock in a report on Thursday, January 4th. Finally, Zacks Investment Research lowered Teva Pharmaceutical Industries from a “hold” rating to a “sell” rating in a report on Friday, January 12th. Eleven analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $19.82.

TEVA stock traded up $0.50 during midday trading on Monday, reaching $17.78. The stock had a trading volume of 6,955,358 shares, compared to its average volume of 14,403,401. The company has a debt-to-equity ratio of 1.91, a quick ratio of 0.58 and a current ratio of 0.86. The firm has a market capitalization of $17,856.36, a P/E ratio of 4.52, a PEG ratio of 1.53 and a beta of 0.67. Teva Pharmaceutical Industries has a 52-week low of $10.85 and a 52-week high of $33.82.

In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 5,050 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $19.68, for a total value of $99,384.00. Following the completion of the transaction, the executive vice president now directly owns 44,517 shares of the company’s stock, valued at approximately $876,094.56. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 10,734 shares of company stock valued at $204,795. 7.10% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Schwab Charles Investment Management Inc. grew its position in Teva Pharmaceutical Industries by 2.5% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 247,560 shares of the company’s stock valued at $4,358,000 after acquiring an additional 5,989 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Teva Pharmaceutical Industries by 4.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,035,835 shares of the company’s stock valued at $18,231,000 after acquiring an additional 46,229 shares in the last quarter. California State Teachers Retirement System grew its position in Teva Pharmaceutical Industries by 1.0% in the 3rd quarter. California State Teachers Retirement System now owns 613,392 shares of the company’s stock valued at $10,796,000 after acquiring an additional 5,860 shares in the last quarter. Pennsylvania Trust Co grew its position in Teva Pharmaceutical Industries by 27.4% in the 4th quarter. Pennsylvania Trust Co now owns 126,600 shares of the company’s stock valued at $2,399,000 after acquiring an additional 27,200 shares in the last quarter. Finally, Greylin Investment Mangement Inc. grew its position in Teva Pharmaceutical Industries by 9.0% in the 4th quarter. Greylin Investment Mangement Inc. now owns 250,545 shares of the company’s stock valued at $4,748,000 after acquiring an additional 20,680 shares in the last quarter. 58.20% of the stock is owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Mesa Laboratories  Downgraded by BidaskClub to “Buy”
Mesa Laboratories Downgraded by BidaskClub to “Buy”
$0.78 EPS Expected for Park Hotels & Resorts  This Quarter
$0.78 EPS Expected for Park Hotels & Resorts This Quarter
$0.36 Earnings Per Share Expected for REV Group Inc  This Quarter
$0.36 Earnings Per Share Expected for REV Group Inc This Quarter
Sandy Spring Bank Sells 620 Shares of Celgene
Sandy Spring Bank Sells 620 Shares of Celgene
SpartanNash  Holdings Raised by LSV Asset Management
SpartanNash Holdings Raised by LSV Asset Management
Kaiser Aluminum  Holdings Cut by LSV Asset Management
Kaiser Aluminum Holdings Cut by LSV Asset Management


© 2006-2018 Ticker Report. Google+.